AKST4290

· Alkahest, Inc.

Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for AKST4290, covering 2022-10-10 to 2023-11-01. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Evaluate the Efficacy of Oral AKST4290 in Participants With Moderately Severe to Severe Diabetic Retinopathy (CAPRI) [Phase 2]

See pricing